Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Through the interactions, macrophages make the immunosuppressive microenvironment proinflammatory, enabling immune attacks on cancer cells and enhancing the effectiveness of checkpoint inhibitors ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: February 28 at 5:53:09 PM EST Loading Chart for CHKP ...

Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of haematological malignancies; however, their application in solid tumors remains challenging. CAR technology ...